@nazliokumusmd.bsky.social
Interventional/Structural Cardiologist at CVI CFl
CardioNerds IC Council Chair
CircAHA SoMe editor
SCAI_WIN
SCAI PAC
NCDR CATHPCI
CardioNerds IC Council Chair
CircAHA SoMe editor
SCAI_WIN
SCAI PAC
NCDR CATHPCI
Reposted
1/ In this #OriginalResearch paper in @ahajournals.bsky.social, Bellamo et al evaluate Lp(a) as a prognostic marker for incident and secondary vascular disease in participants from the UK Biobank
Here's a🧵summarizing key aspects of paper
🔗http://bit.ly/3HkLhP6
Let’s unpack the findings ⤵️
Here's a🧵summarizing key aspects of paper
🔗http://bit.ly/3HkLhP6
Let’s unpack the findings ⤵️
August 25, 2025 at 1:33 PM
1/ In this #OriginalResearch paper in @ahajournals.bsky.social, Bellamo et al evaluate Lp(a) as a prognostic marker for incident and secondary vascular disease in participants from the UK Biobank
Here's a🧵summarizing key aspects of paper
🔗http://bit.ly/3HkLhP6
Let’s unpack the findings ⤵️
Here's a🧵summarizing key aspects of paper
🔗http://bit.ly/3HkLhP6
Let’s unpack the findings ⤵️
1/ #AHAJournals #ESC2025 #SimPub alert
🫀The NOTION-2 trial presents 3-year outcomes for 370 low-risk patients, aged 60-75 with a mean STS score of 1.2%, who have severe AS and were randomized to either TAVR or surgery.
🫀27% of these patients had a native bicuspid valve.
🔗 bit.ly/4g9zwYI
🫀The NOTION-2 trial presents 3-year outcomes for 370 low-risk patients, aged 60-75 with a mean STS score of 1.2%, who have severe AS and were randomized to either TAVR or surgery.
🫀27% of these patients had a native bicuspid valve.
🔗 bit.ly/4g9zwYI
Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis | Circulation
Background: Transcatheter aortic valve replacement (TAVR) is increasingly performed
in younger, low surgical risk patients. This NOTION-2 study reports mid-term outcomes
in low-risk patients aged 60-7...
bit.ly
August 30, 2025 at 4:20 PM
1/ #AHAJournals #ESC2025 #SimPub alert
🫀The NOTION-2 trial presents 3-year outcomes for 370 low-risk patients, aged 60-75 with a mean STS score of 1.2%, who have severe AS and were randomized to either TAVR or surgery.
🫀27% of these patients had a native bicuspid valve.
🔗 bit.ly/4g9zwYI
🫀The NOTION-2 trial presents 3-year outcomes for 370 low-risk patients, aged 60-75 with a mean STS score of 1.2%, who have severe AS and were randomized to either TAVR or surgery.
🫀27% of these patients had a native bicuspid valve.
🔗 bit.ly/4g9zwYI
Reposted
🚨 New @CircAHA #ESC2025 SimPub alert!
🚨 HCM isn’t just driven by rare Mendelian mutations. This study highlights the role of intermediate-effect variants (IEVs)—variants with moderate effect & low penetrance—in shaping disease expression. #HCM #SoMeEditor
tinyurl.com/HCM-IEVs
🚨 HCM isn’t just driven by rare Mendelian mutations. This study highlights the role of intermediate-effect variants (IEVs)—variants with moderate effect & low penetrance—in shaping disease expression. #HCM #SoMeEditor
tinyurl.com/HCM-IEVs
Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants | Circulation
Background: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder
primarily linked to rare variants in sarcomere genes, though recently certain non-sarcomeric
genes have emerged as...
tinyurl.com
August 29, 2025 at 2:52 PM
🚨 New @CircAHA #ESC2025 SimPub alert!
🚨 HCM isn’t just driven by rare Mendelian mutations. This study highlights the role of intermediate-effect variants (IEVs)—variants with moderate effect & low penetrance—in shaping disease expression. #HCM #SoMeEditor
tinyurl.com/HCM-IEVs
🚨 HCM isn’t just driven by rare Mendelian mutations. This study highlights the role of intermediate-effect variants (IEVs)—variants with moderate effect & low penetrance—in shaping disease expression. #HCM #SoMeEditor
tinyurl.com/HCM-IEVs
⏰ The countdown is on for #SCAI2025! I’ll be sharing key insights from this
premier #InterventionalCardiology event. What sessions are you most looking
forward to? Let me know below! 👇 @scainews.bsky.social #SoMe Ambassador for #SCAI2025! #SCAI #CardioSky #SCAIWIN #WIC #Medicine #ACCWIC #ACCFIT
premier #InterventionalCardiology event. What sessions are you most looking
forward to? Let me know below! 👇 @scainews.bsky.social #SoMe Ambassador for #SCAI2025! #SCAI #CardioSky #SCAIWIN #WIC #Medicine #ACCWIC #ACCFIT
April 26, 2025 at 3:25 PM
⏰ The countdown is on for #SCAI2025! I’ll be sharing key insights from this
premier #InterventionalCardiology event. What sessions are you most looking
forward to? Let me know below! 👇 @scainews.bsky.social #SoMe Ambassador for #SCAI2025! #SCAI #CardioSky #SCAIWIN #WIC #Medicine #ACCWIC #ACCFIT
premier #InterventionalCardiology event. What sessions are you most looking
forward to? Let me know below! 👇 @scainews.bsky.social #SoMe Ambassador for #SCAI2025! #SCAI #CardioSky #SCAIWIN #WIC #Medicine #ACCWIC #ACCFIT
🚀 Excited to be an official #SoMe Ambassador for #SCAI2025! Join me
May 1–3 in Washington, D.C. for cutting-edge education, networking, and
innovation in #InterventionalCardiology. Follow along for live updates! 🔗
scai.org/scai2025 #SCAI @scainews.bsky.social #CardioSky
May 1–3 in Washington, D.C. for cutting-edge education, networking, and
innovation in #InterventionalCardiology. Follow along for live updates! 🔗
scai.org/scai2025 #SCAI @scainews.bsky.social #CardioSky
April 8, 2025 at 11:07 PM
🚀 Excited to be an official #SoMe Ambassador for #SCAI2025! Join me
May 1–3 in Washington, D.C. for cutting-edge education, networking, and
innovation in #InterventionalCardiology. Follow along for live updates! 🔗
scai.org/scai2025 #SCAI @scainews.bsky.social #CardioSky
May 1–3 in Washington, D.C. for cutting-edge education, networking, and
innovation in #InterventionalCardiology. Follow along for live updates! 🔗
scai.org/scai2025 #SCAI @scainews.bsky.social #CardioSky